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A B S T R A C T
Transcription factor NRF2 orchestrates a cellular defense against oxidative stress and, so far, has been involved
in tumor progression by providing a metabolic adaptation to tumorigenic demands and resistance to che-
motherapeutics. In this study, we discover that NRF2 also propels tumorigenesis in gliomas and glioblastomas by
inducing the expression of the transcriptional co-activator TAZ, a protein of the Hippo signaling pathway that
promotes tumor growth. The expression of the genes encoding NRF2 (NFE2L2) and TAZ (WWTR1) showed a
positive correlation in 721 gliomas from The Cancer Genome Atlas database. Moreover, NRF2 and TAZ protein
levels also correlated in immunohistochemical tissue arrays of glioblastomas. Genetic knock-down of NRF2
decreased, while NRF2 overexpression or chemical activation with sulforaphane, increased TAZ transcript and
protein levels. Mechanistically, we identified several NRF2-regulated functional enhancers in the regulatory
region ofWWTR1. The relevance of the new NRF2/TAZ axis in tumorigenesis was demonstrated in subcutaneous
and intracranial grafts. Thus, intracranial inoculation of NRF2-depleted glioma stem cells did not develop tumors
as determined by magnetic resonance imaging. Forced TAZ overexpression partly rescued both stem cell growth
in neurospheres and tumorigenicity. Hence, NRF2 not only enables tumor cells to be competent to proliferate but
it also propels tumorigenesis by activating the TAZ-mediated Hippo transcriptional program.
1. Introduction
Glioblastomas (GBs) are the most common primary malignant brain
tumors and remain incurable, with a poor survival rate after diagnosis.
They present somatic mutations in receptor tyrosine kinase pathways,
p53 and retinoblastoma, that correlate with their anatomopathological
classification [1]. However, other effectors are less known.
NRF2 (Nuclear factor (erythroid-derived 2)-like 2), encoded by the
gene NFE2L2, is a basic region-leucine zipper transcription factor that
forms heterodimers with small musculoaponeurotic fibrosarcoma pro-
teins (MAFs) in the nucleus [2]. The heterodimer recognizes an en-
hancer sequence termed antioxidant response element (ARE) that is
present in the regulatory regions of more than 200 genes (ARE-genes).
ARE-genes encode a broad network of enzymes involved in phase I, II,
and III biotransformation reactions, antioxidant mechanisms encom-
passing NADPH-, glutathione- and thioredoxin-mediated reactions,
lipid and iron catabolism, autophagy gene expression, etc. Through this
complex transcriptional network, NRF2 coordinates multifaceted re-
sponses to diverse forms of stress for the maintenance of a stable in-
ternal environment [3,4]. It is now accepted that these homeostatic
functions provide a growth advantage to cancer cells in the hostile
tumor microenvironment and promote cancer progression [5], metas-
tasis [6], and resistance to chemo- and radiotherapy [7–9]. Its activity
is generally increased in glioblastoma cell lines [10] and tumors [11],
and elimination of NRF2 expression inhibits the proliferation and self-
renewal of glioma stem cells [11].
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The tumor promoting activity of NRF2 has been attributed to its
homeostatic functions. However, embryonic, pluripotent and cancer
stem cells express high NRF2 levels [12–14] under controlled in vitro
culture conditions, suggesting additional pro-tumorigenic functions.
NRF2 controls the expression of the stemness associated protein Notch1
[15], while NRF2 inactivation affects stem cell renewal [13,14,16].
However, a mechanistic connection between stemness and NRF2 has
not been demonstrated yet. Here, we focused on the Hippo pathway
effector TAZ (Transcriptional co-activator with PDZ-binding motif). The
Hippo pathway is a Ser/Thr phosphorylation-dependent cascade that,
through the YAP and TAZ co-activators of TEADs1-4, participates in
regulation of organ development, cell proliferation, migration, inva-
sion, and stemness in multiple human cancers [17]. TAZ, encoded by
the gene WWTR1, is a crucial element of the Hippo signaling pathway.
Its expression is elevated in several tumor types including gliomas [18]
and correlates with the grade of malignancy, being maximal in glio-
blastomas [19]. Patients with TAZ over-expressing tumors exhibit a
poor prognosis, and, in cell models, TAZ promotes tumor progression,
while its knockdown prevents proliferation, tumorigenicity and inva-
sion of glioma cells [19]. TAZ is exquisitely regulated at the level of
protein stability by a wide range of stress signals such as mechanical
stress, low energy status, hypoxia and osmotic stress [20,21]. These
signals activate the Hippo pathway, leading to TAZ phosphorylation
and subsequent cytoplasmic retention and degradation [22,23]. How-
ever, little is known about the regulation of its encoding gene,WWTR1.
In this study we analyzed if NRF2 might activate the Hippo pathway
at the level of TAZ, taking GBs as a model. We report that NRF2 induces
the expression of WWTR1, which is partly required for its oncogenic
activity. Thus, NRF2 delivers a growth, proliferative and survival signal
through TAZ in glioblastomas, which is not directly related to redox
metabolism or cytoprotection. These results provide a new strategy for
targeted glioblastoma therapy at the level of NRF2 by reducing not only
its cytoprotective function but also the TAZ-dependent growth and
proliferative signature.
2. Materials and methods
2.1. Glioma database analyses
LGG and GB datasets were retrieved from The Cancer Genome Atlas
(https://www.ncbi.nlm.nih.gov/pubmed/27157931) and analyzed for
NFL2L2 and WWTR1 expression (https://xenabrowser.net/; https://
www.ncbi.nlm.nih.gov/pubmed/24120142). Mutations in the Hippo
pathway or other signaling genes were also analyzed from the TCGA
datasets, which were downloaded respectively from cBioPortal (http://
www.cbioportal.org/) and TCGA databases (http://tcga-data.nci.nhi.
gov/docs/publications/lgggbm_2015), using the UCSC cancer browser.
2.2. Cell culture and reagents
The validated cell lines HEK293T, U-373 MG and U-87 MG were
maintained in Dulbecco's Modified Eagle Medium supplemented with
10% fetal bovine serum. Human glioblastoma explants, GB1, GB2, GB3
and GB4, were kindly supplied by Dr Marta Izquierdo (Centro de
Biología Molecular “Severo Ochoa” - Autonomous University of
Madrid). Most experiments with these explants were performed with
GB1 and GB3 because they exhibit the highest proliferative rates. All
experiments were conducted under neurosphere culture conditions as
described previously [24]. Inmortalized human neural stem cells de-
rived from ventral mesencephalon of fetal brain (ReNcell) were plated
onto Corning® Matrigel® hESC-Qualified Matrix (CORNING) and
maintained in Neurobasal medium (Gibco) containing 2% B27 Sup-
plement (Gibco) (v/v), 20 ng/ml recombinant human EGF (Peprotech),
20 ng/ml recombinant human basic FGF (Peprotech), 100 U/ml Peni-
cillin/Streptomycin (Life Technologies) and 1% Amphotericin b solu-
tion (Lonza) in 5% CO2 at 37 °C conditions. Sulforaphane (SFN) and
GSH-MEE were purchased from Sigma-Aldrich. Limiting dilution assays
were performed essentially as described in Ref. [25]. The final data and
the statistical significances were calculated using the Extreme Limiting
Dilution Analysis (ELDA) software (http://bioinf.wehi.edu.au/
software/limdil/index.html) [25].
2.3. Immunoblotting
This protocol was performed as described in Ref. [26]. Briefly, cells
were homogenized in lysis buffer (TRIS pH 7.6 50 mM, 400 mM NaCl,
1 mM EDTA, 1 mM EGTA and 1% SDS) and samples were heated at
95 °C for 15 min, sonicated and pre-cleared by centrifugation. Proteins
were resolved in SDS-PAGE, transferred to Immobilon-P (Millipore)
membranes and proteins of interest were detected with the following
primary antibodies: NRF2 (homemade and validated in Ref. [27]),
NQO1 (ab2346, Abcam), GAPDH (CB1001, Merck Millipore), YAP/TAZ
(8418, Cell Signaling Techonology); pMST (49332, Cell Signaling
Techonology); MST (14946, Cell Signaling Techonology); pLATS (8654,
Cell Signaling Techonology); LATS (3477, Cell Signaling Techonology);
LaminB (sc-6217, Santa Cruz Biotechnology). Proper peroxidase-con-
jugated secondary antibodies were used for detection by enhanced
chemiluminescence (GE Healthcare).
2.4. Lentiviral and retroviral vector production and infection
Pseudotyped lentiviral vectors were produced in HEK293T cells
transiently co-transfected with 10 μg of the corresponding lentiviral
vector pWXL, 6 μg of the packaging plasmid pSPAX2 (12260, Addgene)
and 6 μg of the VSV-G envelope protein plasmid pMD2G (12259,
Addgene) using Lipofectamine Plus reagent according to the manufac-
turer's instructions (Invitrogen). Retrovirus supernatant was prepared
by transfection of phoenix-Ampho cells (Garry Nolan, Baxter
Laboratory in Genetic Pharmacology, Department of Microbiology and
Immunology, Stanford University, 450 Serra Mall) with 5 μg of each
plasmid using Lipofectamine Plus. Lentiviral vector shRNA control
(shco) (1864, Addgene), several shNRF2-1 (NM_006164
TRCN0000273494), shNRF2-2 (NM_006164 TRCN0000007555) and
shTAZ (NM_015472 TRCN0000370007) were purchased from Sigma-
Aldrich (MISSION shRNA). The lentiviral vector pWPXL-NRF2-WT
(NRF2) was homemade using as expression vector pWPXL (control)
(12257, Addgene). The retroviral vectors used were: pBabePuro (1764,
Addgene) and pBabePuroTAZ-WT (TAZ) (generous gift from Kun-Liang
Guan). Cells were infected in the presence of 4 μg/ml polybrene (Sigma-
Aldrich) and selected with 1 μg/ml puromycin (Sigma-Aldrich).
2.5. Chromatin immunoprecipitation (ChIP) assay
This protocol was performed as described in Ref. [26]. Briefly, cells
derived from two different glioblastoma explants were grown under
stemness conditions and allowed to form neurospheres. Neurospheres
were trypsinized and fixed with 1% formaldehyde. For HEK293T, cells
were transfected with plasmid pcDNA3-NRF2-ΔETGE-V5 encoding a
NRF2 cDNA that lacks the high-affinity binding site for KEAP1 and
contains a V5 tag. DNA complexes were immunoprecipitated with ei-
ther anti-NRF2 (homemade) and rabbit anti-IgG (ab37415, Abcam) for
glioblastoma explants or anti-V5 (37–7500, Invitrogen) and mouse anti-
IgG (ab18413, Abcam) antibodies for transfected HEK293T cells. qRT-
PCR was performed with the primers shown in Supplementary Table S1.
Samples from at least 3 independent ChIPs were analyzed.
2.6. Analysis of mRNA levels
Total RNA extraction and qRT-PCR were done as detailed in Ref.
[28]. Primer sequences are shown in Supplementary Table S2. Data
analysis was based on the ΔΔCT method, with normalization of the raw
data to the housekeeping gene GAPDH (Applied Biosystems). All PCRs
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were performed from triplicate samples.
2.7. Xenograft and intracranial tumorigenicity assays
Balb/c athymic Nude-Foxn1nu mice (Harlan) were used for the xe-
nograft (eight-week-old males) and intracranial (six-week-old females)
tumor assays. U-373 MG or U-87 MG cells (106 cells in 0.1 ml PBS) were
inoculated subcutaneously. For xenografts, tumor growth was ex-
amined every 5 days for up to 65 days. Tumor volume = π/6 × (mean
diameter)3 [29]. U-87 MG (105 cells in 2 μl PBS) or GB3 explant glio-
blastoma cells (2 × 105 cells in 2 μl PBS with 5 ng/μl recombinant
human basic FGF and 5 ng/μl recombinant human EGF, both from
Peprotech) were inoculated intracranially at the right hemisphere
(1 mm anterior, 1.8 mm lateral to bregma and 3 mm intra-par-
enchymal). The Intracranial tumor assay protocol was performed as
described previously [30].
2.8. Magnetic resonance imaging (MRI)
MRI experiments were performed on a Bruker AVANCE III system
(Bruker Medical GmbH®) using a 7.0-T horizontal superconducting
magnet, equipped with a gradient insert (60 mm inner diameter) with a
maximum intensity of 360 mT/m and a 1H selective surface coil
(23 mm diameter). For assessing the tumor growth, contrast enhanced
T1-weighted (CE-T1W) imaging was acquired after the intraperitoneal
administration of 0.3M-Gd-diethylenetriaminepentaacetic acid
(Magnevist®) at a dose of 0.2 mmol/kg. Images were obtained with a
spin-echo sequence and the following parameters: repetition
time = 250 ms, echo time = 10 ms, averages = 6, acquisition ma-
trix = 256 × 256, in-plane resolution of 78 × 78 μm2, slice thick-
ness = 1.0 mm and 10 slices in axial orientation (total acquisition time
of 4.8 min). For assessing the edema, T2-weighted (T2W) spin-echo
images were acquired with a rapid acquisition with relaxation en-
hancement sequence and the following parameters: repetition
time = 2500 ms, echo time = 45 ms, averages = 5, RARE factor = 8,
acquisition matrix = 256 × 256, in-plane resolution of 78 × 78 μm2,
slice thickness = 1.0 mm and 10 slices in axial orientation (total ac-
quisition time of 5 min). During the procedure, the mice are anesthe-
tized and their vital signs are controlled. Tumor volumes were mea-
sured from anatomical CE-T1W images with ImageJ software.
2.9. Immunohistochemistry
Four μm-thick sections of paraffin-embedded samples of glio-
blastoma tissue from patients treated at the Instituto de Investigación
Sanitaria La Paz (IdiPaz, Madrid, Spain) were arrayed in a collection of
three tissue microarray slides. Taken together, these slides en-
compassed 26 good tumor cores. Sections were deparaffinized and re-
hydrated in water, and antigen retrieval was carried out by incubation
in 1 mM EDTA, 0.05% Tween 20, pH 8.0 at 50 °C for 45 min.
Endogenous peroxidase and nonspecific antibody reactivity was
blocked with peroxidase blocking reagent (Dako) at room temperature
for 15 min. The sections were then incubated for 60–90 min at 4 °C with
the corresponding peroxidase conjugated primary antibodies for NRF2
(PA1-38312, Thermo Fisher Scientific), TAZ (HPA007415, Sigma-
Aldrich), NQO1 (ab34173, Abcam), ATRX (DIA-AX1, Dianova), IDH1
(DIA-H09, Dianova), ki67 (M7240, Dako) and developed with 3,3′-
diaminobenzidine (DAB). Negative controls with goat serum replacing
the primary antibody were used. The slides were mounted with DPX
(VWR International). Detection was performed with the Envision Plus
Detection System (Dako). All tumors were negative for IDH1 and ATRX
mutations, therefore confirming that according to histological classifi-
cation they were GBs. Densitometric quantification was done using
macros of the ImageJ software.
2.10. Luciferase reporter generation and luciferase assay
Oligonucleotides with 3 tandem repetitions of the putative ARE2,
ARE2-mutaded, ARE5, ARE6, ARE8 and ARE9 were cloned as detailed
in Supplementary Table S3 and previously described [31]. Cells were
transiently transfected with the expression vectors ARE2, ARE2-mu-
tated, ARE5, ARE6, ARE8, ARE9 or positive control ARE-Luc. pTK-Re-
nilla was also transfected as an internal control. Luciferase assays were
performed with the Dual- Luciferase Reporter Assay System (Promega,
E1910) as previously described [32].
2.11. Flow cytometry determination of reactive oxygen species
Intracellular reactive oxygen species (ROS) were detected in a
FACScan flow cytometer (Becton-Dickinson) with hydroethidine (HE)
(ThermoFisher Scientific), which upon oxidation emits orange fluores-
cence (BP 575/24 nm). Cells were incubated for 1 h at 37 °C with 2 μM
HE and then detached from the plate, washed once with cold PBS, and
analyzed immediately.
2.12. Statistical analyses
Data are presented as mean ± S.D. (standard deviation) or S.E.M.
(standard error of the mean) as indicated in each case. Statistical as-
sessments of differences between groups were analyzed using GraphPad
Prism 5 software by the unpaired Student's t-test. For the scatter plots,
the Pearson correlation coefficient (R) and the p-value associated with
this coefficient were analyzed. Statistically significant differences in
Kaplan-Meier survival curves were calculated with the log-rank test.
3. Results
3.1. Analysis of NFE2L2 and WWTR1 expression in glioblastomas (GBs)
We first analyzed the frequency of mutations in the genes KEAP1,
and NFE2L2, encoding the main NRF2 repressor KEAP1 and NRF2, re-
spectively, as well as several other growth-related pathways in 721
brain tumors from The Cancer Genome Atlas (TCGA) database. Only 11
tumors exhibited mutations in KEAP1 or NFE2L2 and only 32 in genes
of the Hippo pathway (Fig. 1A). Low grade gliomas (LGGs) exhibited
frequent mutations in IDH1, encoding Isocitrate Dehydrogenase-1 and
ATRX, encoding ATP-dependent helicase. By contrast, GBs were prone
to mutations in EGFR, encoding Epidermal Growth Factor Receptor, and
PTEN, encoding Phosphatase and Tensin Homolog (Supplementary Fig.
S1A). Additionally, we analyzed the mutation profile of gliomas with
different levels NFE2L2 and WWTR1 expression (Fig. 1B). Low ex-
pression levels of NFE2L2 and WWTR1 were found in tumors with a
high frequency of mutations in IDH1 and ATRX while their high ex-
pression correlated with high frequency of mutations in EGFR and
PTEN. It has been previously reported that LGGs exhibit low NRF2 le-
vels, but the role of this factor in GB is poorly defined. In search for a
mechanistic role of NRF2 in GBs, we focused in the Hippo pathway
because the lack of frequent mutations might allow unmasking its
physiological mechanism of regulation and its pathological subversion.
We found a positive correlation in the levels of NFE2L2 and WWTR1
transcripts in both LGGs and GBs (Fig. 1C and D). Furthermore, we
observed a striking similarity in the prognosis of NFE2L2 and WWTR1
overexpressing gliomas (Fig. 1E) and glioblastomas (Supplementary
Figs. S1B and S1E). Additionally, we divided GBs as primary or sec-
ondary, according to their hypermethylation phenotype G-CIMP
(glioma cytosine-phosphate-guanine (CpG) island methylator pheno-
type) which is associated with the IDH mutations characteristic of
secondary glioblastomas [33,34] (Fig. 1E and Supplementary Figs. S1C,
S1D, S1F and S1G). High expression of NFE2L2 or WWTR1 correlated
with poor prognosis with an average of 1.7 years survival in gliomas
(Fig. 1E) and 3 years in G-CIMP-positive glioblastomas (Supplementary
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Figs. S1D and S1G).
We further investigated NRF2 and TAZ protein levels in a tissue
array of 26 histologically-defined GBs, all of which were negative for
IDH1 and ATRX mutations (Supplementary Fig. S1H). As an added
control of NRF2 activity, we analyzed the downstream regulated gene
product NADP(H) quinone oxidoreductase (NQO1). Fig. 1F shows three
representative GBs with correlatively low, medium and high levels of
NRF2, TAZ and NQO1 proteins. Densitometric quantification further
demonstrated a statistically significant correlation in the expression of
NRF2, TAZ and NQO1 proteins (Fig. 1G and H). Moreover, there was a
positive correlation in the expression of NRF2 and TAZ with the pro-
liferation marker ki67 (Supplementary Figs. S1I and S1J). Considering
the strong correlation observed in prognosis, transcript and protein
levels, in the following experiments we studied a potential mechanistic
connection between NRF2 and TAZ.
Fig. 1. Analysis of NFE2L2 andWWTR1 expression in GBs. (A–E) Analysis of NFE2L2 andWWTR1 expression in 721 gliomas from the TCGA database. (A) Analysis of
somatic mutations in genes of the Hippo pathway, KEAP1 and NFE2L2. (B) Analysis of the most frequent somatic mutations in gliomas (LGGs and GBs) grouped into
high or low levels of NFE2L2 compared to high or low levels of WWTR1. Statistical analysis was performed with Chi-square test for trend and p-value associated as
indicated. (C) NFE2L2 and WWTR1 mRNAs are increased in GBs compared to LGGs. p-values for differences between groups are indicated in each graph and
calculated using Student's t-test. (D) Scatter plot showing positive correlation between NFE2L2 and WWTR1 expression. The Pearson correlation coefficient (R) and
the p-value associated with this coefficient are indicated. (E) Kaplan-Meier survival curves of patients with gliomas. Patients were stratified in two groups using
NFE2L2 or WWTR1 Z-score values. Statistically significant differences in survival between groups were calculated using the log-rank test. (F– H) NRF2 and TAZ
protein levels are positively correlated in GBs. A tissue array of 26 glioblastomas was analyzed. (F) Sections of three representative tumors with antibodies against
NRF2, TAZ and NQO1 (scale bar, 50 μm). (G, H) Scatter plot showing positive correlation between densitometric quantification of DAB-staining (as percentage of
area) of NRF2 and TAZ (G) or NRF2 and NQO1 (H). The Pearson correlation coefficient (R) and the p-value associated with this coefficient are indicated. See also
Supplementary Fig. S1.
M. Escoll, et al. Redox Biology 30 (2020) 101425
4
3.2. Changes in NRF2 expression modify TAZ levels in tumor explants and
cell lines
Four explants originated from independent GBs were lentivirally-
transduced for 7 days with short hairpin RNAs, control (shco) or spe-
cific for NRF2 knock-down (shNRF2) (Fig. 2A and B). Efficient knock-
down of NRF2 was confirmed at both the mRNA and protein levels to
just 10–20% of its original expression levels. As expected, NRF2 knock-
down led to the down-regulation of the bona fide NRF2 target NQO1
but, importantly, also led to a decrease of TAZ transcript and protein
levels without changes in the phosphorylation status of upstream reg-
ulators of the Hippo pathway, MST and LATS.
We further extended these observations to the GB cell lines U-373
MG and U-87 MG. In agreement with the results obtained in the tumor
explants, lentiviral knock-down of NRF2 for 7 days in U-373 MG cells
led to a reduction of NQO1, as a control, as well as WWTR1 and two of
its targets BIRC5 and CTGF (with subtle changes in CD44) (Fig. 2C and
D). By contrast, TAZ knock-down reduced the expression of WWTR1
and its targets but did not have a significant effect on the mRNA levels
of NFE2L2 or NQO1. Similar results were found in U-87 MG cells
(Fig. 2E and F). Besides, NRF2 knock-down did not modify the phos-
phorylation status of the Hippo regulators MST and LATS
(Supplementary Fig. S2A). Moreover, a time-course of lentiviral knock-
down of NRF2 further demonstrated a progressive reduction in tran-
script and protein levels of NQO1 as expected but also of TAZ
(Supplementary Figs. S2B and S2C). As added controls, another shNRF2
lentivirus yielded comparable results (Supplementary Figs. S2D and
S2E) and ectopic expression of NRF2 in the shNRF2-knocked-down cells
rescued WWTR1 levels (Supplementary Fig. S2F). These results show
that NRF2 is required for expression of TAZ.
Fig. 2. NRF2 knocked-down cells exhibit decreased TAZ levels. (A, B) Four human glioblastoma explants (GB1, GB2, GB3 and GB4) were transduced with a lentivirus
encoding control shRNA (shco) or human shNRF2. (A) mRNA levels of NFE2L2 and WWTR1 were determined by qRT-PCR and normalized by GAPDH. Data are
mean ± S.D. (n = 3). Statistical analysis was performed with the Student's t-test. **p≤ 0.01. (B) Representative immunoblots of NRF2, TAZ, NQO1, p-MST, MST,
pLATS, LATS and GAPDH and LaminB as loading controls (n = 3). (C, D), U-373 MG and (E, F) U-87 MG glioblastomas cell lines were transduced with lentiviral
vectors containing shcontrol (shco), human shNRF2 or human shTAZ. (C, E) mRNA levels of NFE2L2, NQO1, WWTR1, BIRC5, CTGF and CD44 were determined by
qRT-PCR and normalized by GAPDH. Data are mean ± S.D. (n = 3). Statistical analysis was performed with the Student's t-test. **p ≤ 0.01; (NS, indicated not
statistically significant). (D, F) Representative immunoblot analysis of NRF2, TAZ, NQO1 and GAPDH and LaminB as loading controls (n = 4). Similar results were
obtained with a different shNRF2 (Supplementary Fig. S2).
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Then, we used genetic and chemical strategies to upregulate NRF2.
Lentiviral over-expression of NRF2 for 4 days led to a modest increase
in TAZ and NQO1 mRNA and protein levels in two primary glio-
blastomas (GB1 and GB3) (Fig. 3A and B) and U-373 MG and U-87 MG
cells (Supplementary Figs. S3A and S3B). The low effect of NRF2
overexpression might be due to the fact that glioma stem cells exhibit
basally high NRF2 levels [35]. Moreover, under similar proliferation
conditions the levels of NRF2 protein andWWTR1 transcript are similar
in the glioblastomas analyzed (Supplementary Figs. S3C and S3D).
Therefore, we analyzed the effect of NRF2 overexpression in the non-
tumorigenic ReNcell stem cell line, which exhibits low NRF2 expression
(Fig. 3C and Supplementary Fig. S3E). Ectopic expression of NRF2 in
these cells led to increased levels of control NQO1 protein and mRNA
but also TAZ and its target CTGF without changes in upstream reg-
ulators MST and LATS of the Hippo pathway (Fig. 3D and E).
In order to analyze the temporal changes in the NRF2 and TAZ
transcriptional signatures, we treated these cells with the NRF2 acti-
vator sulforaphane (SFN, 15 μM). NRF2 was stabilized within the first
3 h of treatment and then slowly decreased to basal levels at 48 h
(Fig. 3F). This change correlated with a gradual accumulation of NQO1
and TAZ, first at the transcriptional level and then at the protein level
(Fig. 3F, G and 3H). AlthoughWWTR1 gene induction was more modest
than that for NQO1, at the protein level TAZ also remained significantly
elevated for at least 48 h (Fig. 3G). Thereafter, CTGF transcript levels
augmented slowly in a fashion consistent with the TAZ increase, further
leading to the accumulation of CTGF protein by 48 h (Fig. 3F and H).
Fig. 3. Genetic and pharmacological up-regulation of NRF2 increases TAZ levels. (A, B) GB1 and GB3 glioblastoma cells were transduced with empty vector or
lentiviral vector for overexpression of NRF2. (A) Representative immunoblot analysis of NRF2, TAZ, NQO1 and GAPDH as a loading control (n = 3). (B) Messenger
RNA (mRNA) levels of WWTR1 were determined by qRT-PCR and normalized by GAPDH. Data are presented as mean ± S.D. (n = 3) **p ≤ 0.01 according to a
Student's t-test. (C) Representative immunoblots of NRF2, TAZ, GAPDH and LaminB as loading controls in ReNcell, GB1 and GB3. (D, E) ReNcell were transduced
with empty vector or lentiviral vector for overexpression of NRF2. (D) Representative immunoblots of NRF2, TAZ, NQO1, CTGF, p-MST, MST, pLATS, LATS and
GAPDH as a loading control (n = 3). (E)Messenger RNA (mRNA) levels of NQO1,WWTR1 and CTGF were determined by qRT-PCR and normalized by GAPDH. Data
are presented as mean ± S.D. (n = 3) **p≤ 0.01 according to a Student's t-test. (F– H) ReNcell cells were treated with sulforaphane (SFN) (15 μM) for the indicated
times. (F) Representative immunoblots of NRF2, TAZ, NQO1, CTGF, GAPDH and LaminB as loading controls (n = 3). (G) Densitometric quantification of TAZ levels
representative blots from (F) relative to GAPDH and LaminB levels. Data are mean ± S.D. (n = 3) *p ≤ 0.05 according to a Student's t-test. (H) Messenger RNA
(mRNA) levels of NQO1, WWTR1 and CTGF were determined by qRT-PCR and normalized by GAPDH. Data are presented as mean ± S.D. (n = 3) **p ≤ 0.01
according to a Student's t-test. The blue area represents the wave of NRF2 dependent transcription and the green area depicts a second wave that involves NRF2 and
also TAZ-dependent transcription. The time for transition from one wave to the other is was chosen as a possible suggestion. See also Supplementary Fig. S3. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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These results suggest a mechanistic connection between NRF2 and the
TAZ transcriptional programme. Thus, a first wave of NRF2-dependent
transcriptional activation that included NQO1 and TAZ (blue area in
Fig. 3H) was followed by a second more modest wave where TAZ levels
were high enough to increase the expression of the CTGF gene (green
area in Fig. 3H).
3.3. The regulation of WWTR1 by NRF2 is not dependent of the redox state
NRF2 reinforces the antioxidant defense to tolerate the redox al-
terations of tumor cells. Therefore, we determined if the reduction of
WWTR1 expression in NRF2-depleted cells could be attributed to a
modification of the redox environment. We silenced NRF2 in the four
GB explants and the two GB cell lines, and measured the levels of re-
active oxygen species (ROS) with the fluorescent probe hydroethidine
(HE) by flow cytometry. As shown in Fig. 4A, NRF2-depletion did not
increase ROS levels in any of the cell lines analyzed except U-87 MG,
and yet there was a drastic reduction of TAZ protein levels, suggesting
that the regulation of WWTR1 by NRF2 is redox-independent. We fur-
ther analyzed NRF2 knocked-down U-87 MG cells after incubation with
the membrane permeable glutathione analog monoethylglutathione
(GSH-MEE). The combination of NRF2 silencing and GSH-MEE ex-
posure led to graded levels of HE fluorescence (Fig. 4B and C), and
again TAZ levels were only dependent on NRF2 expression (Fig. 4D).
These results indicate that NRF2 regulates TAZ by a redox-independent
mechanism.
3.4. The WWTR1 promoter has functional NRF2-binding sites
We then looked for putative NRF2-regulated AREs in the WWTR1
gene by using the Encyclopedia of DNA Elements at UCSC (ENCODE)
(http://www.webcitation.org/query?url=https%3A%2F%2Fgenome.
ucsc.edu%2F&date=2015-07-29) of the human genome (Feb. 2009).
This database contains experimental data from chromatin im-
munoprecipitation (ChIP) studies of several transcription factors.
Although NRF2 is not included, we analyzed three other ARE-binding
factors, MAFK, MAFF and BACH1, for which information is available,
and retrieved 9 putative ARE candidates according to the consensus
sequence for NRF2 binding depicted at the JASPAR database (http://
jaspar.genereg.net/) (Supplementary Table S4A). As shown in Fig. 5A,
some of these AREs locate at transcriptionally active chromatin sites, as
determined by the presence of DNAse and acetylation sensitive regions.
Additionally, a similar analysis of the YAP coding gene (YAP1) showed
three putative AREs with high score (Supplementary Table S4A and
Supplementary Fig. S4A) and in fact, YAP was also down-regulated in
NRF2-silenced GBs (Supplementary Figs. S3B and S3C). Focusing our
study on TAZ, the nine putative AREs of theWWTR1 gene were further
analyzed by ChIP assays for endogenous NRF2 in two glioblastoma
explants (Fig. 5B and Supplemental Table 4B). To avoid potential un-
specific binding, we further confirmed these results with the im-
munoprecipitation of a V5 tagged-NRF2 construct in HEK293T trans-
fected cells (Supplemental Fig. S5A) [36]. Immunoprecipitated DNA
was analyzed by qRT-PCR with specific primers surrounding the puta-
tive AREs (Supplementary Table S1). At least 3 of the 9 putative AREs
analyzed, termed ARE2, ARE5 and ARE6, exhibited high enrichment
although not as strong as the positive controls HMOX1 and NQO1
(Fig. 5B and C and Supplementary Table S4B). No enrichment was
detected with specific primers for ACTB or for an upstream region of
NQO1 that does not contain an ARE (NQO1*) [26], carried as negative
controls. We chose ARE2, ARE5, ARE6, ARE8 and ARE9 for additional
characterization in reporter luciferase assays. Three tandem nucleotide
sequences of these putative AREs were cloned in the promoter region of
a luciferase reporter. As a negative control, we cloned ARE2 mutated in
the most conserved T and G residues (Fig. 5D). Because GBs were dif-
ficult to transfect, we used U-87 MG. We found that NRF2 interference
reduced the luciferase expression of ARE2, ARE5, ARE6 and ARE8 re-
porters while the ARE9 and the ARE2-mutated reporter did not respond
at all (Fig. 5E). Additionally, HEK293T cells transiently co-transfected
with these reporters plus increasing amounts of NRF2-ΔETGE-V5 ex-
hibited increased luciferase activity of ARE2 but not ARE2-mutated
(Supplementary Fig. S5B). Altogether, these results indicate that NRF2
binds and activates several ARE sequences with probably different po-
tency in the WWTR1 gene promoter.
3.5. TAZ rescues neurosphere growth of NRF2 knocked-down glioma stem
cells
Two different glioblastoma explants, GB1 and GB3, and both U-373
MG and U-87 MG cell lines were grown as glioma stem cells in the
proper medium as floating spherical colonies, termed neurospheres
[24,30,37]. These neurospheres correspond to glioma stem cells and it
is now accepted that they are responsible for anticancer drug resistance
and tumor relapse. Therefore, we tested the effect of depleting either
NRF2 or TAZ under neurosphere growth conditions. Lentiviral knock-
down of NRF2 or TAZ yielded GB1 (Fig. 6A- 6C), GB3 (Fig. 6D- 6F), U-
87 MG cells and U-373 MG cells (data not shown) unable to grow as
Fig. 4. The regulation of WWTR1 by NRF2 is not
dependent of the redox state. (A) U-87 MG and U-373
MG glioblastoma cells and four human glioblastoma
explants (GB1, GB2, GB3 and GB4) were transduced
with lentiviral vectors containing shcontrol (shco) or
human shNRF2 and changes in intracellular ROS
were determined by HE staining (n = 3). (B–D) U-87
MG glioblastoma cells were transduced with lenti-
viral vectors containing shco or human shNRF2 and
treated with GSH-MEE (10 mM, 16 h). (B, C) Flow
cytometry analysis of shNRF2-induced intracellular
ROS production in HE stained cells. A representative
sample of 10,000 cells is shown for each condition.
(D) Representative immunoblots of NRF2, TAZ and
GAPDH as a loading control (n = 3).
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neurospheres. Moreover, glioma stem cell frequency was decreased as
determined in limiting dilution assays (Supplementary Table S5A),
demonstrating that both proteins are required for cancer stem cell
growth. In rescue experiments, we combined NRF2 knock-down with
ectopic retroviral expression of TAZ in glioblastomas explants GB1
(Fig. 6G- 6I), GB3, (Fig. S6J- 6L), U-87 MG (Supplementary Fig. 6A-C)
and U-373 MG (Supplementary Fig. 6D- 6F). Regarding neurosphere
growth (Fig. 6H, I, K, L, Supplementary Figs. S6B, S6C, S6E and S6F),
TAZ also partially rescued the number of neurospheres and glioma stem
cell frequency (Supplementary Table S5B). Altogether, these results
point to TAZ as an instrumental effector of NRF2-driven cancer stem
cell growth.
3.6. The NRF2/TAZ axis is essential for tumorigenesis of GBs
We assessed the tumorigenicity of NRF2- or TAZ-knocked down
glioma stem cells in xenotransplanted athymic mice. The growth of
subcutaneous xenografts was substantially reduced by silencing the
expression of either transcription factor in U-87 MG cells (Fig. 7A and
7B) or U-373 MG cells (Supplementary Figs. S7A and S7B). In mice
intracranially inoculated with U-87 MG cells, the survival rate was
roughly 30 days and increased up to 40 and 60 days by selective si-
lencing of NRF2 or TAZ, respectively (Fig. 7C).
In order to better reproduce the human pathology, we orthotopi-
cally implanted GB3 primary tumor cells and monitored tumor forma-
tion in the brain by magnetic resonance imaging (Fig. 7D and E). These
cells developed tumors that, like in humans, exhibited heterogeneous
and diffused borders with peritumoral and systemic brain edema
(Supplemental Fig. 7C). Primary GB3 cells developed tumors before 10
days. However, when the same cells were knocked-down for expression
of NRF2 or TAZ, they did not generate tumors at least after 30 days
(Fig. 7D and E).
In additional rescue experiments we tested the relevance of TAZ as
an effector of NRF2-mediated tumorigenicity. TAZ over-expression in
control cells expressing basal levels of NRF2 did not lead to a statisti-
cally significant increase in tumor volume. However, TAZ over-ex-
pression restored by 20% the growth of tumors derived from NRF2-
knocked-down U-87 MG (Fig. 7F and G) and U-373 MG cells
(Supplementary Figs. S7D and S7E). In intracranial tumors, mouse life
expectancy decreased from 45 days in the control NRF2-silenced cells to
35 days in the TAZ rescued cells (Fig. 7H). These results indicate that
TAZ is one effector of NRF2-induced tumorigenicity in GBs.
4. Discussion
An effective therapy for GB would be possible if its molecular pa-
thology was better known. In the TCGA database we found that somatic
mutations in the NRF2 and Hippo pathways are rare (Fig. 1A) whereas
EGFR and PTEN mutations are very frequent. However, NRF2 levels
were high in these glioma stem cells compared to the non-tumorigenic
neural stem cell line ReNcell, therefore demonstrating an abnormal up-
regulation of NRF2 in GBs. These results suggest that NRF2 activation
might be connected with subversion of signaling pathways that impinge
on EGFR or PTEN. We have previously reported that chemical or ge-
netic inhibition of PTEN in prostate and endometrial cancers leads to
the activation of NRF2. This is due to the constitutive inhibition of
glycogen synthase kinase-3 (GSK-3), thus relieving NRF2 from the GSK-
3/beta-TrCP ubiquitin-proteasome pathway [27,32,38].
We also found that the transcript levels ofWWTR1 exhibit the same
trend as NRF2 to be increased in GBs, suggesting that they might be
mechanistically connected. Genetic (shRNA and NRF2 overexpression)
and chemical (sulforaphane) manipulation of NRF2 indicated that the
transcript and protein levels of TAZ and TAZ-dependent genes are, at
least in part, governed by the levels of NRF2. We have also observed
that TAZ knock-down decreases NRF2 protein (Fig. 2D, F, 6A and 6D)
but not transcript levels (Fig. 2C and E). One possible explanation is
Fig. 5. The WWTR1 promoter has functional NRF2-
binding sites. (A) Representative scheme of the gene
WWTR1 encoding TAZ. Regions enriched in acety-
lated histone H3 lysine 27 (H3K27ac) are shown in
blue and regions sensitive to DNase are represented
as dark boxes. Experimental sequences reported to
bind MAFK, MAFF and BACH1 factors were analyzed
for the presence of AREs (ARE 1–9). (B, C) ChIP
analysis of putative AREs found in (A) using the anti-
NRF2 antibody vs. a control IgG in glioblastoma ex-
plant cells GB1 (B) and GB3 (C). (D) Luciferase re-
porter constructs used for assessment of ARE2, ARE2
mutated, ARE5, ARE6, ARE8 or ARE9 functionality in
pGL3basic vector. (E) U-87 MG glioblastomas cell
lines were transduced with lentiviral vectors con-
taining shco and human shNRF2 and transfected with
ARE2, ARE2 mutated, ARE5, ARE6, ARE8 or ARE9.
Luciferase activity was measured 24 h after trans-
fection. Luciferase activities were normalized to re-
nilla activity. Results are shown relative to control
and are mean ± S.D. (n = 3). **p≤ 0.01 according
to a Student's t-test. See also Supplementary Table S1,
Table S3, Table S4, Supplementary Fig. S4 and Fig.
S5. (For interpretation of the references to colour in
this figure legend, the reader is referred to the Web
version of this article.)
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that by silencing TAZ, there is a depletion in the expression of signaling
genes such as CTGF and AREG of the EGF family of growth factors
which by means of an autocrine loop might regulate NRF2 stability
through GSK-3/beta-TRCP [17,27,32]. Because TAZ responds to stress
signals, we analyzed if the changes in TAZ levels could be attributed to
an indirect effect that might result from variations in oxidative stress
when NRF2 is silenced. However, under cancer stem cell growth con-
ditions, the depletion of NRF2 did not lead to measurable redox changes
except in U-87 MG cells. Although at first glance this finding may seem
surprising, it should be noted that up-regulation of NRF2 not only
provides redox tolerance, but also a metabolic switch towards the
pentose phosphate pathway that leads to NADPH and ribose production
as precursors for cell growth and division. This metabolic reprograming
may be particularly important in tumors with low growth rate where
redox alterations are not so relevant and yet need growth precursors. In
any case, the fact that U-87 MG submitted to GSH-MEE did not alter
TAZ levels further suggests that NRF2 can regulate TAZ in a redox-
independent manner.
We identified several putative AREs in the WWTR1 gene promoter.
The most potent ARE located at a highly DNAse-sensitive and H3K27-
acetylated region, suggesting that it is accessible to the transcriptional
machinery, but was not as potent as the canonical ARE of HMOX1,
which is rapidly induced upon NRF2 activation. Several studies have
analyzed the NRF2 transcriptional signature by microarray or RNA-
sequencing approaches [8,39]. From these studies it is possible to dis-
tinguish grades of gene response to NRF2, from the most sensitive ones,
Fig. 6. Ectopic expression of TAZ rescues neurosphere growth of NRF2-knocked-down glioma stem cells GB1 (A–C) and GB3 (D–F) cells were transduced with
lentivirus encoding shco, human shNRF2 or human shTAZ. (A, D) Representative immunoblot analysis of NRF2, TAZ and GAPDH as a loading control (n = 3). (B, E)
Representative images of tumor neurosphere formation. Scale bar, 100 μm. (C, F) Quantification of the number of secondary neurospheres or the number of cells
represented as percentage relative to shco. Data presented mean ± S.D. (n = 3) **p ≤ 0.01 according to a Student's t-test. GB1 (G–I) and GB3 (J–L) cells were
transduced with empty retrovirus as control or a retrovirus expressing TAZ, and then with a lentivirus expressing shco or shNRF2. (G, J) Representative immunoblot
analysis of NRF2, TAZ and GAPDH as a loading control (n = 3). (H, K) Representative images of tumor neurosphere formation. Scale bar, 100 μm. (I, L)
Quantification of the number of secondary neurospheres and the number of cells represented as a percentage relative to control-shco. Data are presented as
mean ± S.D. (n = 3) **p ≤ 0.01 according to a Student's t-test. See also Supplementary Fig. S6 and Supplementary Table S5.
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related to the classical redox control, to others that need more time and
persistent presence of NRF2. For instance, genes involved in metabolic
reprograming or autophagy appear to require persistent exposure to
NRF2 [26,40]. Therefore, we suggest that a low but persistent level of
TAZ expression elicited by NRF2 may contribute to promotion of tu-
morigenesis in GBs. Considering that cell specific epigenetic changes
may hinder regulatory sequences, the relevance of this NRF2/TAZ axis
needs to be evaluated under the particular conditions of each cellular
model.
Glioma stem cells were strictly dependent of NRF2 expression to
develop spheroids and tumors, in agreement with a previous study
[41], as NRF2 knocked-down xenografts exhibited a dramatic reduction
Fig. 7. The NRF2/TAZ axis is essential for tumorigenesis of GBs. (A, B) U-87 MG glioblastoma cells were transduced with a lentivirus encoding shco, human shNRF2
or human shTAZ and implanted subcutaneously in athymic mice. (A) Growth curves of xenograft tumors. Data are presented as mean ± S.E.M. (n = 4). *p≤ 0.05
according to a Student's t-test. (B) Upper panel, representative tumors of each experimental condition at the end point (scale bar, 1 cm); lower graph, quantification
of the final tumor volume. Data are presented as mean ± S.E.M. (n = 4). *p ≤ 0.05 according to a Student's t-test. (C) Kaplan-Meier survival curves of mice
orthotopically implanted in the brain. Log-rank test between shco and shNRF2 is indicated (n = 6). (D, E) GB3 glioblastoma explant cells were transduced with a
lentivirus encoding shco, human shNRF2 or human shTAZ and orthotopically implanted in the brain in athymic mice. (D) Representative image of T1 MRI of each
experimental condition after 10, 20 and 30 days post-surgery. Green arrows indicate the tumor in shco or the injection scar in shNRF2 or shTAZ. (E) Growth curves of
brain tumors. Data are presented as mean ± S.E.M. (n = 6) **p≤ 0.01 according to a Student's t-test. (F, G) U-87 MG cells were transduced with empty retrovirus
or a retrovirus expressing TAZ and then with lentivirus encoding shco or shNRF2 and implanted subcutaneously in athymic mice. (F) Growth curves of xenograft
tumors. Data are presented as mean ± S.E.M. (n = 4). *p ≤ 0.05 according to a Student's t-test. (G) Upper panel, representative tumors of each experimental
condition at the end point (scale bar, 1 cm); lower graph, quantification of the final tumor volume. Data are presented as mean ± S.E.M. (n = 4). *p ≤ 0.05
according to a Student's t-test. (H) Kaplan-Meier survival curves of mice orthotopically implanted in the brain. Log-rank test between control/shNRF2 and TAZ/
shNRF2: p = 0.056 (n = 5). See also Supplementary Fig. S7. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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in tumor formation following subcutaneous and intracranial inocula-
tion. Interestingly, TAZ overexpression partially restored stem cell
growth and tumorigenicity, further demonstrating that TAZ is an ef-
fector of NRF2 to support stemness. However, this effect was modest,
suggesting that NRF2 uses additional pathways to elicit tumorigenicity.
In fact, besides it role in redox regulation, recent studies further suggest
that NRF2 regulates pathways involved in tumorigenesis and self-re-
newal such as Shh ([42], Wnt [43] and Notch [44].
It would be expected that the Hippo pathway is silent in cancer cells
for TAZ to remain transcriptionally active. However, among the 721
gliomas analyzed, only 4.4% exhibited mutations that might potentially
inactivate the Hippo pathway (Fig. 1A and [45]). Moreover, TAZ ex-
pression was increased in these tumors, therefore indicating additional
mechanisms for TAZ up-regulation. Our study identifies NRF2 as one
such mechanism, hence probably counteracting repressor signals and
providing a tumor growth advantage.
An efficient therapy for GBs must consider that high NFE2L2 and
WWTR1 levels are predictors of chemoresistance [46,47]. Indeed,
overexpression of NRF2 and TAZ correlated with resistance to the al-
kylating agent temozolomide, which is the gold standard treatment for
gliomas. At this time, no selective NRF2 inhibitor is available, but at
least as a proof-of-concept, we found that genetic knock-down of NRF2
drastically reduced TAZ transcriptional signature and stemness in
gliomas. Contrary to EGFR and PTEN, the observation that NFE2L2 is
not frequently mutated in GBs and that yet NRF2 is strictly necessary to
sustain tumorigenesis of glioblastoma stem cells provides a rationale to
use drugs that could modulate NRF2 activity as a downstream effector
of these mutated genes.
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